New hope for scleroderma patients: tofacitinib takes on skin thickening
NCT ID NCT07472166
First seen Apr 17, 2026 · Last updated May 15, 2026 · Updated 3 times
Summary
This study tested whether tofacitinib, a drug that calms the immune system, works better than methotrexate for reducing skin thickening in people with a severe form of scleroderma. 34 adults with early-stage diffuse scleroderma took part. The main goal was to measure changes in skin hardness over 24 weeks using a standard scoring system.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SCLERODERMA, SYSTEMIC are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Department of Rheumatology, Bangabandhu Sheikh Mujib Medical University (BSMMU)
Dhaka, 1000, Bangladesh
Conditions
Explore the condition pages connected to this study.